Résumé
In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria organs. These findings will have major bearing in expanding the limited liver donor pool, and may save lives where up to a quarter of listed patients die on wait-lists. Herein we offer a brief overview of the history and current status of ex situ liver perfusion, and discuss future directions that will likely have major impact on the practice of clinical liver transplantation.
Langue d'origine | English |
---|---|
Pages (de-à) | 132-141 |
Nombre de pages | 10 |
Journal | Transplantation Reviews |
Volume | 32 |
Numéro de publication | 3 |
DOI | |
Statut de publication | Published - juill. 2018 |
Publié à l'externe | Oui |
Note bibliographique
Funding Information:Funding: MB is the recipient of the American Society of Transplant Surgeons (ASTS) 2015 Scientist Scholarship. AMJS holds a Canada Research Chair in Transplantation Surgery and Regenerative Medicine, and a Senior Clinical Scholarship from Alberta Innovates Healthcare Solutions. Funding from the University Hospital Foundation at the University of Alberta is gratefully acknowledged. Funding from Astellas Pharma Canada is gratefully acknowledged.
Publisher Copyright:
© 2018 Elsevier Inc.
ASJC Scopus Subject Areas
- Transplantation